# Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap

Study · id `cardio:ct-nct02593149` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02593149](<https://clinicaltrials.gov/study/NCT02593149>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02593149

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1902 participants.

## Technical summary

Registry record NCT02593149. Randomized; no masking; primary purpose treatment. Start 2015-11 (actual); primary completion 2016-11 (actual). Results posted on 2019-02-27.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1902 participants (enrolled count; ClinicalTrials.gov record NCT02593149, source copy `cardio:ctgov-nct02593149-2019-02-27`, retrieved 2026-10-26)
- Started: 2015-11 (actual) (ClinicalTrials.gov record NCT02593149, source copy `cardio:ctgov-nct02593149-2019-02-27`, retrieved 2026-10-26)
- Primary completion: 2016-11 (actual) (ClinicalTrials.gov record NCT02593149, source copy `cardio:ctgov-nct02593149-2019-02-27`, retrieved 2026-10-26)
- Completion: 2016-11 (actual) (ClinicalTrials.gov record NCT02593149, source copy `cardio:ctgov-nct02593149-2019-02-27`, retrieved 2026-10-26)
- Results first posted: 2019-02-27 (ClinicalTrials.gov record NCT02593149, source copy `cardio:ctgov-nct02593149-2019-02-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02593149, source copy `cardio:ctgov-nct02593149-2019-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02593149-2019-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
- Condition: End Stage Renal Disease (ESRD)
- Intervention (Device): ClearGuard HD End Cap
- Lead sponsor: Pursuit Vascular, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Davita Clinical Research
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection (`cardio:pubmed-29472415`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: df48edfd19dcae1da475b177fa4fa22e6b446db089e6df22f2e98eca52e6a1fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
